20% ORIGINAL ISSUE DISCOUNT UNSECURED CONVERTIBLE DEBENTURE DUE [______________, 2016]Convertible Security Agreement • August 12th, 2016 • Protea Biosciences Group, Inc. • Pharmaceutical preparations • New York
Contract Type FiledAugust 12th, 2016 Company Industry JurisdictionTHIS 20% ORIGINAL ISSUE DISCOUNT UNSECURED CONVERTIBLE DEBENTURE is one of a series of duly authorized and validly issued 20% Original Issue Discount Unsecured Convertible Debentures of Protea Biosciences Group, Inc., a Delaware corporation, (the “Company”), having its principal place of business at 1311 Pineview Drive, Suite 501, Morgantown, WV 26505, designated as its 20% Original Issue Discount Unsecured Convertible Debenture due [_______, 2016]1 (this debenture, the “Debenture” and, collectively with the other debentures of such series, the “Debentures”).
FORM OF COMMON STOCK PURCHASE WARRANT PROTEA BIOSCIENCES GROUP, INC.Security Agreement • August 12th, 2016 • Protea Biosciences Group, Inc. • Pharmaceutical preparations
Contract Type FiledAugust 12th, 2016 Company IndustryTHIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the three year anniversary of the Final Closing Date under the Subscription Agreement (the “Termination Date”) but not thereafter, to subscribe for and purchase from Protea Biosciences Group, Inc., a Delaware corporation (the “Company”), up to [ ] shares (the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SUBSCRIPTION AGREEMENTSubscription Agreement • August 12th, 2016 • Protea Biosciences Group, Inc. • Pharmaceutical preparations • New York
Contract Type FiledAugust 12th, 2016 Company Industry JurisdictionSUBSCRIPTION AGREEMENT (this “Agreement”) made as of the last date set forth on the signature page hereof between Protea Biosciences Group, Inc. (the “Company”), and the undersigned (the “Subscriber”).